Stealth's lead drug flunks again, this time in an eye dis­ease, but biotech will at­tempt to push for­ward

Stealth Bio­Ther­a­peu­tics’ lead drug has failed a Phase II study in an eye dis­ease, deal­ing an­oth­er blow to the biotech’s elamipre­tide as the treat­ment had al­ready been re­fused by the FDA for Barth syn­drome last au­tumn.

The drug flunked on the pri­ma­ry goals of low lu­mi­nance vi­su­al acu­ity and ge­o­graph­ic at­ro­phy pro­gres­sion in pa­tients with GA sec­ondary to dry age-re­lat­ed mac­u­lar de­gen­er­a­tion. The Boston biotech thinks a sec­ondary end­point from the Re­CLAIM-2 study show­ing vi­su­al func­tion im­prove­ment is enough to con­tin­ue de­vel­op­ing the drug in GA with the help of fu­ture part­ners, tout­ing reti­nal mi­to­chon­dr­i­al health as an im­por­tant sign of po­ten­tial.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER